Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Palomino Laboratories Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2024
FY2025
General and administrative
0.08
0.01
2.7
Operating expenses
0.01
2.7
Operating income
-0.08
-0.01
-2.7
Interest expense
0.01
Interest income
0
0
Net income
-0.08
-0.02
-3.16
EPS, basic
-0.01
-0.01
-0.47
EPS, diluted
-0.01
-0.01
-0.47
Shares, basic (weighted)
13.2
1.52
6.71
Shares, diluted (weighted)
13.2
1.52
6.71
Balance sheet
FY2023
FY2024
FY2025
Cash and equivalents
0
0.13
8.12
Other current assets
0
0.31
Total current assets
0
0.14
8.43
Total assets
0
0.14
8.43
Accounts payable
0
0
0.06
Total current liabilities
0.11
0.01
0.34
Other non-current liabilities
0.15
Total liabilities
0.11
0.16
0.34
Paid-in capital
-0
11.3
Retained earnings
-0.11
-0.02
-3.18
Shareholders' equity
-0.02
-0.02
8.1
Total equity
-0.02
-0.02
8.1
Total liabilities and equity
0
0.14
8.43
Shares outstanding
13.2
4.5
18.8
Cash flow statement
FY2023
FY2024
FY2025
Net income
0.08
-0.02
-3.16
Stock-based compensation
1.44
Change in payables
-0.01
0.01
Cash from operations
-0.08
-0
-1.28
Cash from financing
0.08
0.2
9.27
Net change in cash
-0
-0
7.99
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $14.00 on November 2, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-25.2%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-24.6%
Net income / average total assets.
Return on invested capital (ROIC)
-349.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
6,006.0%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
340.5%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
53.1x
Current assets / current liabilities.
Quick ratio
52.7x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
52.7x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$0.16
Cash from operations / diluted weighted shares.
Book value per share
$0.89
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
18.8x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
18.8x
Market cap / tangible book value, when positive.
Earnings yield
-1.3%
Net income / market cap (the inverse of P/E).
Was Palomino Laboratories Inc. profitable in fiscal 2025?
No. It reported a net loss of $3.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.